294 related articles for article (PubMed ID: 22475046)
1. Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.
Lundgren K; Brown M; Pineda S; Cuzick J; Salter J; Zabaglo L; Howell A; Dowsett M; Landberg G;
Breast Cancer Res; 2012 Apr; 14(2):R57. PubMed ID: 22475046
[TBL] [Abstract][Full Text] [Related]
2. 'Arimidex' (anastrozole) versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer--efficacy overview.
Buzdar AU;
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):399-403. PubMed ID: 14623537
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Madeira M; Mattar A; Logullo AF; Soares FA; Gebrim LH
BMC Cancer; 2013 Sep; 13():425. PubMed ID: 24047421
[TBL] [Abstract][Full Text] [Related]
4. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
[TBL] [Abstract][Full Text] [Related]
5. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
6. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
[TBL] [Abstract][Full Text] [Related]
7. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
Aapro MS; Forbes JF
Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
[TBL] [Abstract][Full Text] [Related]
8. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Cuzick J; Sestak I; Baum M; Buzdar A; Howell A; Dowsett M; Forbes JF;
Lancet Oncol; 2010 Dec; 11(12):1135-41. PubMed ID: 21087898
[TBL] [Abstract][Full Text] [Related]
9. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J;
Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
[TBL] [Abstract][Full Text] [Related]
11. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer.
Bostner J; Ahnström Waltersson M; Fornander T; Skoog L; Nordenskjöld B; Stål O
Oncogene; 2007 Oct; 26(49):6997-7005. PubMed ID: 17486065
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer.
Iwata H; Masuda N; Sagara Y; Kinoshita T; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Tsuda H; Hayashi N; Noguchi S
Cancer; 2013 Feb; 119(4):704-13. PubMed ID: 22972694
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
[TBL] [Abstract][Full Text] [Related]
14. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
Sgroi DC; Sestak I; Cuzick J; Zhang Y; Schnabel CA; Schroeder B; Erlander MG; Dunbier A; Sidhu K; Lopez-Knowles E; Goss PE; Dowsett M
Lancet Oncol; 2013 Oct; 14(11):1067-1076. PubMed ID: 24035531
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
[TBL] [Abstract][Full Text] [Related]
16. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
Dowsett M; Cuzick J; Wale C; Forbes J; Mallon EA; Salter J; Quinn E; Dunbier A; Baum M; Buzdar A; Howell A; Bugarini R; Baehner FL; Shak S
J Clin Oncol; 2010 Apr; 28(11):1829-34. PubMed ID: 20212256
[TBL] [Abstract][Full Text] [Related]
17. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
18. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
19. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis.
Jonat W; Gnant M; Boccardo F; Kaufmann M; Rubagotti A; Zuna I; Greenwood M; Jakesz R
Lancet Oncol; 2006 Dec; 7(12):991-6. PubMed ID: 17138220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]